Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 16/20 | 0.80 |
| ▸ | FLT3 | P36888 | 5/20 | 0.80 |
| ▸ | KIT | P10721 | 4/20 | 0.80 |
| ▸ | AURKA | O14965 | 2/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
| ▸ | RET | P07949 | 1/20 | 0.80 |
| ▸ | MET | P08581 | 1/20 | 0.80 |
| ▸ | SRC | P12931 | 1/20 | 0.80 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.80 |
| ▸ | KDR | P35968 | 1/20 | 0.80 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.80 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.80 |
| ▸ | MERTK | Q12866 | 1/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.80 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.80 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639408 | 1.00 | AXL (0.80) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121452 | 0.92 | AXL (0.81) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL2056553 | 0.92 | AXL (0.81) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30090868 | 0.92 | AXL (0.81) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL467836 | 0.92 | AXL (0.81) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL20351831 | 0.91 | AXL (0.79) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL30121445 | 0.91 | AXL (0.77) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL2056599 | 0.91 | AXL (0.77) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL467995 | 0.91 | AXL (0.77) | AXLFLT3KITAURKAEGFR | |
| SCHEMBL24819579 | 0.90 | AXL (0.79) | AXLFLT3KITAURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2024-08-22 | — | — | US | disclosed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 29/4885KIT 2149/4885 |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 33/4885KIT 2345/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885FLT3 28/4885KIT 2025/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885FLT3 1/4885KIT 1463/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885FLT3 33/4885KIT 890/4885 |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885FLT3 29/4885KIT 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.